Stormy waters – Oncology R&D is a fine line between success and over the edge sometimes!
BSB Reader Mailbag – With the FDA approval of lurbinectedin on Monday and two very different recent announcements regarding adjuvant therapy readouts for CDK4/6 inhibitors, we received a bunch of BSB reader questions on both topics.
It’s been a while since we dived into the mailbag in a busy conference season, so this is a great time to reflect on some broader thoughts in oncology R&D for context.
Here, we look at two key aspects…
- Am I enthused about the lurbinectedin data or not?
- What half dozen factors could we be thinking about when considering CDK4/6 inhibitors in adjuvant HR+/HER2- breast cancer in order to decide if one is better than the other or does luck play a part?
To learn more from our oncology analysis and get a heads up on insights and commentary emerging from recent company announcements, subscribers can log-in or you can click to gain access to BSB Premium Content.
The many faces of lung cancer requires an appreciation of nuance in treatment
Barcelona – Many observers seem to so be single mindedly focused on immunotherapies of late that they may well be forgiven that, hey, there’s still much going on the world of targeted therapies!
If there is one thing we can learn from the lung cancer (and CML) communities it is their dedication to identifying resistance mechanisms and along with them, novel targets for subsequent therapy in order to set about improving outcomes for people with the disease.
As a result, lung cancer can now be segmented into many subsets, each requiring careful consideration of appropriate therapy options, not only in newly diagnosed disease, but also what to do with subsequent lines of therapy.
In this review, our third from the WCLC 2019 meeting, we pull together a lot of disparate loose ends on targeted therapies and draw some important themes together…
To learn more from our latest oncology conference insights and get a heads up on the evolving science and resistance mechanisms, subscribers can log-in or you can click to gain access to BSB Premium Content.